Is Organon (OGN) Quietly Recasting Its Cardiovascular Strategy With the Nilemdo Deal in Northern Europe?

Simply Wall St.01-11

In early January 2026, Daiichi Sankyo Europe announced an agreement for Organon to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway, targeting patients ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602155255?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice2-main-header/1585186851278","is_english":true,"pubTime":"2026-01-11 23:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602155255","market":"hk","top_or_hot":-1,"title":"Is Organon (OGN) Quietly Recasting Its Cardiovascular Strategy With the Nilemdo Deal in Northern Europe?","media":"Simply Wall St.","content":"<div>\n<p>In early January 2026, Daiichi Sankyo Europe announced an agreement for Organon to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway, targeting patients ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-ogn/organon/news/is-organon-ogn-quietly-recasting-its-cardiovascular-strategy\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Organon (OGN) Quietly Recasting Its Cardiovascular Strategy With the Nilemdo Deal in Northern Europe?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Organon (OGN) Quietly Recasting Its Cardiovascular Strategy With the Nilemdo Deal in Northern Europe?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-11 23:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-ogn/organon/news/is-organon-ogn-quietly-recasting-its-cardiovascular-strategy><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In early January 2026, Daiichi Sankyo Europe announced an agreement for Organon to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway, targeting patients ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-ogn/organon/news/is-organon-ogn-quietly-recasting-its-cardiovascular-strategy\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-ogn/organon/news/is-organon-ogn-quietly-recasting-its-cardiovascular-strategy","article_id":"2602155255","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice2-main-header/1585186851278"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-ogn/organon/news/is-organon-ogn-quietly-recasting-its-cardiovascular-strategy","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602155255","pubTimestamp":1768144745,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In early January 2026, Daiichi Sankyo Europe announced an agreement for Organon to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway, targeting patients with high cholesterol and elevated cardiovascular disease risk who are not well served by statins.\nThis commercialization deal adds a differentiated cardiovascular product to Organon’s portfolio in key European markets, expanding its role in addressing high unmet need among statin-intolerant...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","BK4588":"碎股","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","BK4559":"巴菲特持仓","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK4585":"ETF&股票定投概念","CSII":"Cardiovascular Systems","OGN":"Organon & Co","BK4082":"医疗保健设备","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC"},"translate_title":"Organon(OGN)是否正在通过北欧的Nilemdo交易悄悄重塑其心血管战略？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OGN":1.5,"CSII":1.5},"content_text":"In early January 2026, Daiichi Sankyo Europe announced an agreement for Organon to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway, targeting patients with high cholesterol and elevated cardiovascular disease risk who are not well served by statins. This commercialization deal adds a differentiated cardiovascular product to Organon’s portfolio in key European markets, expanding its role in addressing high unmet need among statin-intolerant patients, including many women. We’ll now examine how this new Nilemdo® commercialization partnership in Northern Europe could influence Organon’s existing investment narrative and future prospects. This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.AdvertisementOrganon Investment Narrative RecapTo own Organon, you need to believe it can offset pressure on mature, off patent brands by building a higher value mix across women’s health, biosimilars and licensed assets. The Nilemdo® deal broadens that mix in cardiovascular care, but it is not large enough, on its own, to change the main near term story around earnings pressure from loss of exclusivity and pricing. The most relevant recent data point is that analysts expect upcoming quarterly earnings of US$0.74 per share on revenue of US$1.53 billion, both down year on year. Against that backdrop, the Nilemdo® commercialization agreement in Northern Europe looks incremental to the existing catalyst of improving product mix, while the core risks around generic competition and funding pressure in women’s health remain very much in focus. However, investors should also be aware that continued pricing pressure and exposure to off patent products could still... Read the full narrative on Organon (it's free!)Organon’s narrative projects $6.5 billion revenue and $990.3 million earnings by 2028.Uncover how Organon's forecasts yield a $9.36 fair value, a 16% upside to its current price.Exploring Other PerspectivesOGN 1-Year Stock Price Chart Eight fair value estimates from the Simply Wall St Community span roughly US$5 to over US$70 per share, showing very different views of Organon’s potential. You can set those opinions against the current reliance on mature, off patent products and decide how that risk might influence the company’s longer term performance.Explore 8 other fair value estimates on Organon - why the stock might be worth 38% less than the current price!Build Your Own Organon NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Organon research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.Our free Organon research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Organon's overall financial health at a glance.Ready To Venture Into Other Investment Styles?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:Uncover the next big thing with financially sound penny stocks that balance risk and reward.The latest GPUs need a type of rare earth metal called Neodymium and there are only 39 companies in the world exploring or producing it. Find the list for free.These 18 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602155255","isCrawlerRequest":true}